Peptide Protocol

App Store

TB-500 vs Thymosin Beta-4: clearing up the naming

TB-500 is sold on grey-market peptide sites as a synthetic version of Thymosin Beta-4 (Tβ4). The naming suggests they're the same molecule. They're usually not. Most commercial "TB-500" is a 7-amino-acid active fragment (the LKKTETQ sequence) — useful for some research applications, distinct from the full protein in dosing, pharmacokinetics, and risk profile.

The two molecules

Why LKKTETQ exists as a separate molecule

The full Thymosin Beta-4 protein has multiple functional regions. Research in the 1990s–2000s identified a small heptamer (Leu-Lys-Lys-Thr-Glu-Thr-Gln) that retains some of the wound-healing and actin-binding effects of the parent protein. The fragment is much easier and cheaper to manufacture synthetically.

The fragment is biologically active in some assays (e.g., epithelial wound healing in cell culture, angiogenesis in animal models). It is not equivalent to the full protein in every assay. Some functions of full Tβ4 (immune modulation, cardiac repair) appear to require the larger structure.

The vendor confusion

"TB-500" started as a research designation for the fragment. Grey-market vendors adopted the name and often advertise it as:

• "Synthetic Thymosin Beta-4" — technically misleading; it's a fragment, not synthetic full Tβ4.
• "Bioequivalent to Tβ4" — not validated; the fragment has different pharmacokinetics.
• "Premium Tβ4" at premium pricing — yet the fragment is cheaper to produce.

Some legitimate research-supply companies do sell full-length Thymosin Beta-4 — usually at much higher prices ($500+ for a few mg vs $30–60 for the fragment). The pricing gap is a tell.

How to know which you have

1. Check the COA molecular weight. Full Tβ4 is ~4,963 Da. Fragment is ~860 Da. Any reputable vendor lists MW on the COA.
2. Check the sequence on the COA. Full Tβ4 starts SDKPDMAEIE... and is 43 amino acids long. LKKTETQ fragment is 7 amino acids.
3. Look at the price. Full Tβ4 at <$80 for 5 mg is almost certainly the fragment, mislabeled.
4. Check stability claims. Full Tβ4 has different reconstitution and storage characteristics than the fragment.

What this means clinically

Both molecules are unapproved for human use (see FDA warnings on BPC-157 and TB-500). Beyond that:

• The fragment has less human data than the parent protein. Even what little Tβ4 human data exists doesn't necessarily transfer to the fragment.
• Dosing protocols circulated online (e.g., "5 mg twice a week") originated for the fragment based on rough scaling from rodent studies. Whether they translate to therapeutic effect is unverified.
• Immunogenicity differs. A short fragment is less likely to trigger anti-protein immune responses than a full 43-residue molecule. But fragments can have their own antigenicity issues, particularly if process impurities are present.
• Tolerance and tachyphylaxis patterns reported by long-term users may relate to neutralizing antibodies against the fragment, against impurities, or against both.

The thymosin alpha-1 footnote

There's a third name in this family: thymosin alpha-1 (Tα1), an unrelated 28-residue peptide. Tα1 is approved in some countries (not the U.S.) for hepatitis B/C and HIV adjunctive therapy. Some grey-market vendors confuse the naming. Tα1, Tβ4, and TB-500 are three different molecules with three different mechanisms and three different bodies of evidence.

FAQ

Related reading

Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.